Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides

  • STATUS
    Recruiting
  • End date
    Sep 30, 2023
  • participants needed
    100
  • sponsor
    New Discovery LLC
Updated on 21 February 2022
tenofovir
fumarate
lamivudine
liver disease
adefovir
antiviral therapy
entecavir
antiviral drugs
chronic hepatitis
telbivudine
tenofovir alafenamide 25 mg

Summary

Both tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are potent antiviral agents for hepatitis B virus (HBV) and recommended by the American Association for the Study of Liver Disease (AASLD) as well as the European Association for the Study of Liver (EASL) guidelines for the treatment of nucleos(t)ide therapy induced HBV resistance. However, it is not clear if chronic hepatitis B (CHB) patients with nucleos(t)ide treatment experience without genotypic mutations would be benefit from TAF therapy. Previous studies have observed that suboptimal response (SOR) following antiviral therapy with nucleos(t)ide treatment is associated with an increased risk of subsequent treatment failure and viral resistance. It remains unclear whether switching to TAF is a reasonable approach in patients with SOR to second-line antivirals Lamivudine (LAM)/ Telbivudine (LdT)/ Adefovir Dipivoxil (ADV) and its combinations with other second-line antivirals for 24 weeks, or SOR to the first-line antiviral Entecavir (ETV) or any antiviral combinations containing ETV for 48 weeks. This study is aimed to determine how the aforementioned patients with SOR to nucleos(t)ide treatment respond to TAF monotherapy. The investigator's study will provide evidence base for therapy selection in SOR patients, especially in China where the majority of patients with CHB are treated with nucleos(t)ide therapy.

Description

This is a prospective, single-arm, multicenter cohort study evaluating the efficacy, safety, and tolerability of TAF monotherapy in in Asian CHB adults with SOR to the nucleos(t)ide therapy by assessing the HBV DNA suppression in 48 weeks. Approximately one hundred adults who received the aforementioned nucleos(t)ide therapy will be prospectively enrolled during the period from December 2019 to June 2021. Subjects will be enrolled by medical clinic in about 10 university centers in different regions in China. Approximately 10-15 consecutive eligible patients will be enrolled from each participating sites. This study will be conducted in accordance with the guidelines of Good Clinical Practices (GCPs) including Institutional Review Board (IRB) approval and consent will be applied. Patient identification (ID) will be de-identified for submitting to the central database for analyses from all study sites. Free TAF treatment will be provided to all enrolled patients for 48 weeks. Patients will be under the local standard of care upon the completion of the current study.

Patients aged 18-80 with CHB infection who had received nucleos(t)ide therapy over 24 weeks of LAM/LdT/ADV or 48 weeks of ETV with medication adherence, but failure to achieve the levels of HBV-DNA below 300 IU/mL will be eligible. Subjects will be excluded if they meet the following criteria: co-infected with HIV or other viral hepatitis; the serum levels of HBV DNA are too low (i.e. about 300 IU/mL) to be analyzed for the genotypic mutation(s); nucleos(t)ide resistant mutants have been detected at screening visit, patient is under a clinical research protocol of phase I-III development; unable to consent or unlikely to complete one year follow up after the enrollment; and other medical condition may affect the ability to participate the study.

Details
Condition Hepatitis B, Chronic
Treatment Tenofovir Alafenamide 25 MG
Clinical Study IdentifierNCT04201808
SponsorNew Discovery LLC
Last Modified on21 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients must be 18-80 years of age
Patients must have documented compensated and stable chronic hepatitis B defined by all of the following
HBsAg persistently positive > 6 months
Clinical history, physical findings, and test results are compatible with compensated chronic hepatitis B
Patients must have received nucleos(t)ide therapy consisting of LAM/LdT/ADV and its combinations with other second-line antivirals for 24 weeks, or with the first-line antiviral ETV or any antiviral combinations containing ETV for 48 weeks with medication adherence
Although having undergone therapy, patients have had failure to achieve the levels of HBV-DNA below 300 IU/mL
Patient is willing and able to comply with the study drug regimen and all other study requirements
Patient must understand the risk, and be willing and able to provide written informed consent to participate in the study

Exclusion Criteria

Pregnant women, and women who are breastfeeding or who believe they may wish to become pregnant during the course of the study
Males and females of reproductive potential who are not willing to use an effective method of contraception during the study. For males, condoms should be used and for females, a barrier contraception method should be used in combination with one other form of contraception
Unwilling and/or unable to provide written informed consent
Patients with CHB but are also co-infected with HIV or other viral hepatitis
Patients whose serum levels of HBV DNA are too low (i.e. about 300 IU/mL) to be analyzed for the genotypic mutation(s) at the onset of this trial, i.e. baseline
At the screening visit, nucleos(t)ide resistant mutants have been detected in the strain of HBV of the patient
The patient is under a clinical research protocol of phase I-III development; unable to consent or unlikely to complete one year follow up after the enrollment; and other medical condition may affect the ability to participate the study
Decompensated liver disease defined as direct (conjugated) bilirubin 1.2 Upper Limit of Normal (ULN); Prothrombin Time (PT) 1.2 ULN, platelets 150,000/mm3, or serum albumin 3.5 g/dL
Prior history of clinical hepatic decompensation (e.g., ascites, jaundice, encephalopathy) or variceal hemorrhage
Serum -fetoprotein 50 ng/mL
Evidence of hepatocellular carcinoma (HCC)
History of significant renal disease (e.g., nephrotic syndrome, renal dysgenesis, polycystic kidney disease, congenital nephrosis, acute tubular necrosis, other renal disease)
History of significant bone disease (e.g., osteomalacia, chronic osteomyelitis, osteogenesis imperfecta, osteochondrosis, multiple bone fractures)
Significant cardiovascular, pulmonary or neurological disease
Evidence of a gastrointestinal malabsorption syndrome that may interfere with absorption of orally administered medications
History of solid organ or bone marrow transplantation
Ongoing therapy with any of the following: Nephrotoxic agents
Parenteral aminoglycoside antibiotics (e.g., gentamicin, tobramycin, amikacin)
Cidofovir
Cisplatin
Foscarnet
IV amphotericin B
IV pentamidine
Oral or IV ganciclovir
Cyclosporine
Tacrolimus
IV vancomycin
Chronic daily non-steroidal anti-inflammatory drug therapy
Competitors of renal excretion (e.g., probenecid) Systemic chemotherapeutic agents
Systemic corticosteroids
Interleukin-2 (IL-2) and other immunomodulating agents
Investigational agents (except with the expressed approval of the lead investigators)
Note: administration of any of the above medications must be discontinued at
least 30 days prior to the Baseline Visit and for the duration of the study
period
Known hypersensitivity to the study drugs, the metabolites or formulation excipients
Any other condition (including alcohol or substance abuse) or prior therapy that, in the opinion of the Investigators, would make the subject unsuitable for the study or unable to comply with dosing requirements
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note